Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 5
1984 5
1985 5
1986 13
1987 7
1988 8
1989 12
1990 10
1991 7
1992 7
1993 8
1994 5
1995 12
1996 11
1997 6
1998 10
1999 7
2000 9
2001 8
2002 13
2003 7
2004 7
2005 6
2006 10
2007 6
2008 8
2009 12
2010 8
2011 6
2012 7
2013 5
2014 3
2015 5
2016 7
2017 7
2018 1
2019 4
2020 2
2021 4
2022 7
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

290 results

Results by year

Filters applied: . Clear all
Page 1
Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.
Corren J, Larson D, Altman MC, Segnitz RM, Avila PC, Greenberger PA, Baroody F, Moss MH, Nelson H, Burbank AJ, Hernandez ML, Peden D, Saini S, Tilles S, Hussain I, Whitehouse D, Qin T, Villarreal M, Sever M, Wheatley LM, Nepom GT, Sanda S; Immune Tolerance Network ITN057AD CATNIP Study Team. Corren J, et al. Among authors: nepom gt. J Allergy Clin Immunol. 2023 Jan;151(1):192-201. doi: 10.1016/j.jaci.2022.08.029. Epub 2022 Oct 9. J Allergy Clin Immunol. 2023. PMID: 36223848 Clinical Trial.
Antigen recognition.
Sette A, Nepom GT. Sette A, et al. Among authors: nepom gt. Curr Opin Immunol. 2000 Feb;12(1):77-9. doi: 10.1016/s0952-7915(99)00053-9. Curr Opin Immunol. 2000. PMID: 10712002 No abstract available.
A first-in-human, open-label Phase 1b and a randomised, double-blind Phase 2a clinical trial in recent-onset type 1 diabetes with AG019 as monotherapy and in combination with teplizumab.
Mathieu C, Wiedeman A, Cerosaletti K, Long SA, Serti E, Cooney L, Vermeiren J, Caluwaerts S, Van Huynegem K, Steidler L, Blomme S, Rottiers P, Nepom GT, Herold KC; AG019-T1D-101 Trial Investigators. Mathieu C, et al. Among authors: nepom gt. Diabetologia. 2024 Jan;67(1):27-41. doi: 10.1007/s00125-023-06014-2. Epub 2023 Oct 2. Diabetologia. 2024. PMID: 37782353 Free PMC article. Clinical Trial.
MHC class II tetramers.
Nepom GT. Nepom GT. J Immunol. 2012 Mar 15;188(6):2477-82. doi: 10.4049/jimmunol.1102398. J Immunol. 2012. PMID: 22389204 Free PMC article. Review.
Approaches to Establishing Tolerance in Immune Mediated Diseases.
Huffaker MF, Sanda S, Chandran S, Chung SA, St Clair EW, Nepom GT, Smilek DE. Huffaker MF, et al. Among authors: nepom gt. Front Immunol. 2021 Sep 20;12:744804. doi: 10.3389/fimmu.2021.744804. eCollection 2021. Front Immunol. 2021. PMID: 34616405 Free PMC article. Review.
Distinct trajectories distinguish antigen-specific T cells in peanut-allergic individuals undergoing oral immunotherapy.
Calise J, DeBerg H, Garabatos N, Khosa S, Bajzik V, Calderon LB, Aldridge K, Rosasco M, Ferslew BC, Zhu T, Smulders R, Wheatley LM, Laidlaw TM, Qin T, Chichili GR, Adelman DC, Farrington M, Robinson D, Jeong D, Jones SM, Sanda S, Larson D, Kwok WW, Baloh C, Nepom GT, Wambre E; IMPACT. Calise J, et al. Among authors: nepom gt. J Allergy Clin Immunol. 2023 Jul;152(1):155-166.e9. doi: 10.1016/j.jaci.2023.03.020. Epub 2023 Mar 30. J Allergy Clin Immunol. 2023. PMID: 37003475
290 results